Merck’s allergy business Allergopharma opened in March 2017 its new biopharmaceutical production in Reinbek, near Hamburg (Germany). The new capacity is a cornerstone in the global expansion of Allergopharma, a leading player in the allergen immunotherapy (AIT) of type I allergies, such as hay fever or allergic asthma. The factory covers 6,000 square meters and it is characterised by an entirely glass cleanroom, in which the company will manufacture its products for causal treatment. The new building has ultra-modern technological operations, a glass visitors’ foyer with a view of the cleanrooms and the potential for extension to accommodate further filling lines.